Aidoc has secured $150 million to accelerate development of the company's clinical-grade CARE Foundation Model.
Clinical AI Reasoning Engine, CARE, is trained on multimodal data, and two CARE-powered products have earned U.S. Food and Drug Administration (FDA) clearance, the company noted in its announcement. All Aidoc models will transition to CARE, Aidoc said, adding that it plans for CARE to cover 90% of clinically relevant diseases, including cancer and cardiovascular conditions, within three years.
The funding will also support expansion of the company's enterprise-grade operating system infrastructure, aiOS, as well as accelerate efforts to develop an open ecosystem.
As part of its update, Aidoc said it currently supports care for more than 45 million patients annually across over 150 health systems. New enterprise-wide rollouts -- for Advocate Health in Wisconsin and North Carolina, and a West Coast hub at Sutter Health in California -- were announced in the past month.
Aidoc's other leading health system partners include Mount Sinai Health System, Yale New Haven Health System, Northwell Health, University of Miami Health System, and Temple Health.
"Our mission is to reduce diagnostic errors and improve patient outcomes," said Aidoc CEO Elad Walach in the announcement, in which the company estimated that 371,000 deaths occur annually as a result of diagnostic errors. "CARE compresses decades of roadmap into years, bringing forward a future where AI supports every patient encounter."
The funding round was led by General Catalyst and Square Peg, with participation from NVentures (NVIDIA's venture capital arm) and four major U.S. health systems, including Hartford HealthCare, Mercy, Sutter Health, and WellSpan Health, Aidoc said. With this round, Aidoc's total funding has reached $370 million.
Through strategic initiatives with NVIDIA and [Amazon Web Services] AWS, Aidoc will invest the money to bring CARE to market.
